All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Live-attenuated SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC
Highest Development Status: Phase I Product Type: Vaccine
Recipient: Codagenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Designed as a randomized, double-blinded, placebo-controlled dose-escalation study, the Phase 1 trial will evaluate a total of 48 volunteers at multiple dose levels to determine the safety and tolerability COVI-VAC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: COVISHIELD
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2021
Details:
SII, which is developing Covishield is seeking emergency approval for its vaccine on the basis of the interim safety and immunogenicity data from the Phase 2 and 3 trials, along with the findings of overseas clinical studies done on 23,745 participants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 10-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Pneumosil
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
The vaccine called PNEUMOSIL® will primarily help to fight against pneumococcal pneumonia amongst children and will be available at an affordable competitive price with an advantage of presence of serotypes 6A and 19A in the vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVI-VAC
Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC
Highest Development Status: Phase I Product Type: Vaccine
Recipient: Codagenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Codagenix and the Serum Institute of India announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Government of Bangladesh
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 05, 2020
Details:
5 million doses of ChAdOx1 nCoV-19 per month would be purchased through Bangladesh’s drug maker, Beximco Pharmaceuticals. Serum Institute would provide the vaccine at a price similar to that which India pays.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase II Product Type: Vaccine
Recipient: ABEC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2020
Details:
ABEC’s Custom Single Run (CSR®) is supporting Serum Institute of India in delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 29, 2020
Details:
The expansion brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDX-005
Therapeutic Area: Infections and Infectious Diseases Product Name: CDX-005
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Codagenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
Drugs Controller General of India (DCGI) to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
